Glucosaminyl muramy ldipeptide in treatment and prevention of infectious diseases

Abstract

Infectious diseases and their spread make a challenge to actualize immunoprophylaxis and immunotherapy in order to increase the reserves of the immune system in forming an adequate response to the pathogen. Numerous studies by clinicians and fundamental scientists are devoted to finding an effective solution to this problem. An example of the successful use of these advances in the treatment and prevention of infectious diseases is the use of glucosaminyl muramyl dipeptide (GMDP), which specifically activates NOD2-receptors, responsible for the realization of innate and acquired immunity. The review provides examples of the complex use in practical medicine of the drug Lkopid based on GMDP for the treatment of infectious diseases. The main schemes of immunoprophylaxis and immunotherapy of diseases of bacterial and viral etiology with the help of muramyl dipeptide of different age groups are highlighted. Particular attention is paid to the possibility of using GMDP for specific prophylaxis of viral infections.

Keywords:infectious diseases, glucosaminyl muramyl dipeptide, immunotherapy, immunoprophylaxis, innate immunity

Funding. The study has no sponsor support.

Conflict of interests. Authors declare no conflict of interests.

Contribution. The authors declare equal contributions to the writing of the article.

For citation: Guryanova S.V., Khaitov R.M. Glucosaminylmuramyl dipeptide in treatment and prevention of infectious diseases. Infectious diseases. News, Opinions, Training 2020; 9 (3): 79-86. DOI: https://doi.org/10.33029/2305-3496-2020-9-3-79-86

References

1. Khaitov R.M., Garib F.Yu. Immunology. Atlas. Moscow: GEOTAR-Media. 2016. 416 p. (in Russian)

2. Khaitov R.M. Immunomodulators: myths and reality. Immunologiya [Immunology]. 2020; 41 (2): 101–6. DOI: 10.33029/0206-4952-2020-41-2-101-106 (in Russian)

3. Yamamura Y., Onoue K., Azuma I. Biology of the mycobacterioses. Chemical and immunological studies on peptides and polysaccharides from tubercle bacilli. Ann N Y Acad Sci. 1968; 154 (1): 88–97.

4. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974; 59 (4): 1317–25.

5. Shann, F. The non-specific effects of vaccines. Arch. Dis. Child. 2010; 95: 662–7.

6. Stensballe L.G., Nante E., Jensen I.P., Kofoed P.E., Poulsen A., Jensen H., et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine. 2005; 23: 1251–7.

7. Wardhana, Datau E.A., Sultana A., Mandang V.V., Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med. Indones. 2011; 43: 185–90.

8. Ogawa C., Liu Yuen-Joyce, Kobayashi K.S. Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy. Curr Bioact Compd. 2011; 7 (3): 180–97. DOI: 10.2174/157340711796817913

9. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003; 278 (11): 8869–72. DOI: 10.1074/jbc.C200651200

10. Behr M.A., Divangahi M., Adjuvant F. NOD2 and Mycobacteria. Curr Opin Microbiol. 2015; 23: 126–32. DOI: 10.1016/j.mib.2014.11.015

11. O’Reilly T., Zak O. Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin Infect Dis. 1992; 14 (5): 1100–9. DOI: 10.1093/clinids/14.5.1100

12. Pinegin B.V., Kulakov A.V., Makarov E.A., Ledger P.W., Khaitov R.M. The occurrence of natural antibodies to minimal component of bacterial cell wall (N-acetylglucosaminyl-N-acetylmuramyl dipeptide) in sera from healthy humans. Immunol Lett. 1995; 47 (1-2): 33–7. DOI: 10.1016/0165-2478(95)00079-k

13. Meshcheryakova E., Makarov E., Philpott D., Andronova T., Ivanov V. Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminy N-acetylmuramyl peptides. Vaccine. 2007; 25: 4515–20.

14. Tsujimoto M., Kinoshita F., Okunaga T., Kotani S., Kusumoto S., Yamamoto K., et al. Higher immunoadjuvant activities of N-acetyl-beta-D-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine in comparison with N-acetylmuramyl-L-alanyl-D-isoglutamine. MicrobiolImmunol. 1979; 23 (9): 933–6.

15. Meshcheryakova E.A., Guryanova S.V., Makarov E.A., Andronova T.M., Ivanov V.T. Structure-function investigation of glucosamuramyl peptides. Influence of chemical modification of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) on its immunomodulatory properties in vivo and in vitro. Bioorganicheskaya Khimiya [Bioorganic Chemistry]. 1991; 17: 1157–65. (in Russian)

16. Serkova N.A., Serkov I.L., Kulakov A.V. The use of a new domestic immunocommodator Likopid to reduce seasonal incidence. Immunologiya [Immunology]. 2000; (3): 62–3. (in Russian)

17. Filatova C.V., Simonova A.V., Artemyev M.E., Golubeva N.M. Features of the clinical and immunological effects of Likopid in some chronic diseases of ENT organs. Immunologiya[Immunology]. 2001; (2): 37–42. (in Russian)

18. Guryanova S.V., Borisova O.Yu., Kolesnikova N.V., Lezhava N.L., Kozlov I.G., Gudima G.O. The effect of muramyl peptide on the microbial composition of the microflora of the oral cavity. Immunologiya[Immunology]. 2019; 40 (6): 34–40. DOI: 10.24411 / 0206-4952-2019-16005 (in Russian)

19. Stagnieva I.V., Simbirtsev A.S. Immunotherapy efficiency in rhinosinusitis patients. Medical Immunology (Russia). [Meditsinskaya Immunologiya]. 2015; 17 (5): 423–30. DOI: 10.15789/1563-0625-2015-5-423-430 (in Russian)

20. Svistunova A.S., Arshinova S.S., Klimova Ye.G., Simonova A.V., Mazurov D.V., Golubeva N.M., et al. Clinical and immunological efficiency of immunomodulator licopide in pulmonary tuberculosis. [Immunologiya]. 2000; (5): 59–62. (in Russian)

21. Sukhov V.M., Gnezdilova E.V. The experience of using ofloxacin, lycopid and psychological correction in patients with chronic pulmonary tuberculosis. Pulmonologiya [Russian Pulmonology]. 2002; 4: 9–12. (in Russian)

22. Savelyeva M.V. The effectiveness of the use of immunocorrection of lycopid in the complex treatment of patients with tuberculous pleurisy: Abstract. Diss. Sciences. St. Petersburg. 1999: 24 p. (in Russian)

23. Chernetsova L.F., Boltovich A.V., Zorina L.I., Subach E.B. Lycopid and cycloferon in the complex treatment of chlamydial genital infections in women. Tyumenskiy meditsinskiy zhurnal [Tyumen Medical Journal]. 2001; (4): 11–2. (in Russian)

24. Melkova I.B. Systemic immunotherapy with lycopid and local superlymph in the complex treatment of chlamydia: Abstract of Diss. Chelyabinsk, 2005: 25 p. (in Russian)

25. Apchel A.V., Ivanov A.M. Immunotherapy of chronic trichomoniasis in men. Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2010; (4): 82–6. (in Russian)

26. Kiryukhin A.V., Parfenova N.A., Maksimova T.A. Optimization of treatment for children who are often ill for a long time: immunocorrection with Lycopid. Rossiiskii Pediatricheskii Zhurnal [Russian Pediatric Journal]. 2001; (5): 279. (in Russian)

27. Baranova I.D., Sredshchikova I.A. The effectiveness of bacterial immunomodulators in children with chronic diseases of the respiratory tract. Health. Actual issues of immunology and allergology. Edited by I.A. Snizhshchikov, S.M. Yudin. Orel, 2004; 2: 21–5. (in Russian)

28. Bakhmetyev B.A., Kevorkov N.N., Tokmakova O.G., Ezova E.A. The use of lycopid in complex asymptomatic immunocorrection in children from ecologically unfavorable areas. Allergologiya i immunologiya [Allergology and Immunology]. 2000; 1 (2): 33–5. (in Russian)

29. Chuvirov D.G., Yartsev M.N. Clinical and immunological efficacy of Licopid in children with repeated upper respiratory tract infections. Immunologiya [Immunology]. 2000; (2): 4850. (in Russian)

30. Mayorov R.V., Chereshneva M.V., Verzilin S.D., Chereshnev V.A. The effectiveness of the use of immunocorrective drugs for the prevention of respiratory infections and their complications in frequently ill children of primary school age. Meditsinskaya immunologiya [Medical Immunology]. 2013; 15 (3): 25562. (in Russian)

31. Ivanova V.V., Ivanova M.V., Levina A.S., Zakina A.A., Tikhomirova O.V., Zheleznikova G.F., et al. Current principles in the treatment and diagnosis of perinatal herpesvirus infections. Rossiyskiy Vestnik Perinatologii i Pediatrii [Russian Bulletin of Perinatology and Pediatrics]. 2008; (1): 18. (in Russian)

32. Soboleva N.G., Shapovalova T.I., Osipova I.G. The results of a double-blind randomized study of the clinical efficacy of lycopid in the complex treatment of cytomegalovirus hepatitis in children. Pediatriya [Pediatrics]. 2008; 87 (2): 1003. (in Russian)

33. Khaitov R.M., Pinegin B.V., Pashenkov M.V. Epithelial cells of the respiratory tract as equal participants of innate immunity and potential targets for immunotropic drugs. Immunologiya[Immunology]. 2020; 41 (2): 107–13. DOI: 10.33029/0206-4952-2020-41-2-107-113 (in Russian)

34. Guryanova S.V., Khaitov R.M. Glucosaminylmuramyldipeptide – GMDP: effect on mucosal immunity (on the issue of immunotherapy and immunoprophylaxis). Immunologiya[Immunology]. 2020; 41 (2): 174–83. (in Russian)

35. Abramashvili Yu.G., Kolesnikova N.V., Borisova O.Yu., Guryanova S.V. Low molecular weight bioregulator of bacterial origin in condylomatosis therapy optimization. Vestnik Rossiyskogo universiteta druzhby narodov. Seriya: Meditsina [RUDN Journal of Medicine]. 2020; 4 (2): 163–7. DOI:10.22363/2313-0245-2020-24-2-163-167

36. Manapova E.R., Fazylov V.Kh., Guryanova S.V. Cytopenias and their correction during antiviral therapy of chronic hepatitis C in patients with genotype 1. Voprosy virusologii [Problems of Virology]. 2017; 62 (4): 174–8. DOI: http://dx.doi.org/10.18821/0507-4088-2017-62-4-174-178l (in Russian)

37. Parfenteva I.V., Medvedeva I.V., Chesnokov E.V., Sokolov S.L., Sharapova L.P., Sharapova K.O., et al. Treatment options for interferon-induced neutropenia in patients with chronic hepatitis C. Ural'skiy meditsinskiy zhurnal [Ural Medical Journal]. 2012; (9): 138–41. (in Russian)

38. Gaysina E.Sh., Dudarev M.V., Chuikova N.N. Clinical effectiveness of the domestic immunomodulator glucosamylmuramyl dipeptide (Likopid) in the complex treatment of elderly patients with stable angina pectoris. Prakticheskaya meditsina [Practical medicine]. 2011; (4): 80–5. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»